AltrixBio
AltrixBio is pioneering a new category of metabolic therapeutics with its lead candidate, AJN003, a once-daily oral pill that mimics the distal nutrient shift of gastric bypass surgery. Founded by a team with deep clinical and scientific expertise, the company leverages a bio-engineered compound derived from sucralfate, aiming to deliver glycemic control and weight loss without systemic absorption. With strong pre-clinical data, a clear regulatory strategy, and a platform with potential applications beyond diabetes, AltrixBio is positioned to address significant unmet needs in the growing obesity and metabolic disease markets.
Private Company
Total funding raised: $5M
AI Company Overview
AltrixBio is pioneering a new category of metabolic therapeutics with its lead candidate, AJN003, a once-daily oral pill that mimics the distal nutrient shift of gastric bypass surgery. Founded by a team with deep clinical and scientific expertise, the company leverages a bio-engineered compound derived from sucralfate, aiming to deliver glycemic control and weight loss without systemic absorption. With strong pre-clinical data, a clear regulatory strategy, and a platform with potential applications beyond diabetes, AltrixBio is positioned to address significant unmet needs in the growing obesity and metabolic disease markets.
Technology Platform
A proprietary oral platform that creates a transient, local coating in the upper GI tract to shift nutrient sensing distally, triggering a hormonal and metabolic reset without systemic absorption. It is bio-engineered from sucralfate.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Competes against dominant systemic GLP-1/GIP receptor agonists (Novo Nordisk, Eli Lilly) and oral incretin candidates. Primary differentiation is its local, non-systemic mechanism of action targeting nutrient sensing rather than hormone receptors, which may offer a superior tolerability profile and a unique physiological reset akin to bariatric surgery.